Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV001320074 | SCV001510845 | uncertain significance | Neurofibromatosis, type 2 | 2022-07-06 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Tolerated"; PolyPhen-2: "Possibly Damaging"; Align-GVGD: "Class C0"). ClinVar contains an entry for this variant (Variation ID: 1020490). This variant has not been reported in the literature in individuals affected with NF2-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change replaces lysine, which is basic and polar, with asparagine, which is neutral and polar, at codon 525 of the NF2 protein (p.Lys525Asn). |
Ambry Genetics | RCV002402892 | SCV002709450 | uncertain significance | Hereditary cancer-predisposing syndrome | 2020-07-28 | criteria provided, single submitter | clinical testing | The p.K525N variant (also known as c.1575A>C), located in coding exon 15 of the NF2 gene, results from an A to C substitution at nucleotide position 1575. This variant impacts the first base pair of coding exon 15. The lysine at codon 525 is replaced by asparagine, an amino acid with similar properties. This amino acid position is well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |